Scottish Development International
Scottish Development International (SDI) is Scotland's trade and inward investment agency. We help international companies find partners in Scotland, and Scottish companies develop their business overseas. SDI also works to attract inward investment and knowledge to Scotland. With more than 700 organisations, and almost 47,000 people, the Life Sciences sector in Scotland is one of the largest in Europe. Scotland has strengths in Drug Discovery and Development, Precision Medicine, Digital Health, Diagnostics, and Advanced Therapy Medicinal Products. There are leading companies, expert and innovative solution providers, academic excellence, an availability of talent, and a supportive and connected ecosystem. With a global network of offices, including in the US, Europe and Asia, SDI provides a wide range of services. These include connecting international companies to the Life Sciences sector in Scotland by identifying the right partners, scoping incentives, business mentoring, market intelligence, business location information and investor aftercare.
About Scottish Development International
. .
Seda Pharmaceutical Development Services
Seda Pharmaceutical Development Services specialises in integrated Pharmaceutical Development and Clinical Pharmacology. Our mission is to facilitate the efficient development of optimal medicinal products, from conventional to complex formulations, by leveraging scientific excellence. We are experts in dose selection and justification, including Drug Metabolism and Pharmacokinetics (DMPK)
. .
Serenatis Bio
Serenatis Bio is a forward-thinking biotech company focused on revolutionising the treatment of obsessive-compulsive disorder (OCD) — a mental illness that affects hundreds of millions yet remains under-treated, despite its often devastating impact.
Serenatis Bio is advancing three novel drug candidates targeting OCD, each with unique mechanisms of action, through preclinical development. It is about to complete its pre-seed round of $1.3M, having secured $1.17M from Zinc VC (lead investor), Novaterra Ventures, the Watson Family Office, and P53 Invest. Serenatis is seeking an investor keen to put in the final $130k.
Serenatis Bio will be launching a $30M Series A round in the second half of this year in order to go into clinical trials and would like to speak to investors interested in that round. For more information, please contact Nick Sireau, CEO and Co-founder, on nick@serenatisbio.com
Slide deck (non confidential)
https://biopartnermembers.meeting-mojo.com/uploads/1006/org/20250321-serenatis-bio-full-non-conf-deck-21-march-2025.pdf
